Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical remission at week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
Clinical response as defined by the studies week 4 · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical response as defined by the studies week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether infliximab 10 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
It is very uncertain whether infliximab 10 mg/kg changes clinical response defined by reduction of CDAI score by ≥ 70 at week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improved IBDQ at week 8 · people with active UC
Infliximab leads to higher improved IBDQ at week 8 compared with placebo (high certainty).
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
EQ‐5D at week 6 · people with active UC
1 finding from 1 review
Health‐related quality of life · people with active UC
Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
Infliximab probably leads to higher improved SF‐36 MCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Participants with active Crohn's disease despite current treatment with infliximab
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Infliximab 5 mg/kg may leads to higher clinical remission at week 26 compared with purine analogues (low certainty).
1 finding from 1 review
Clinical response at week 26 · Patients with active Crohn's disease
Infliximab 5 mg/kg may leads to higher clinical response at week 26 compared with purine analogues (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review